Table 2.
BNT162b2 vaccine effectiveness against COVID-19 related hospitalization among children 6–11 years old.
| Population | COVID-19 hospitalizations | Follow up time in days (median, IQR) | Person-days | COVID-19 hospitalization incidence rate (per 1,000,000 person-days) | Univariate | Overall | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | p-value | ||||||
| Vaccination status* | ||||||||||
| Unvaccinated | 1,238,040 | 414 | 242 (242–242) | 431,984,362 | 9.6 | Ref | Ref | Ref | Ref | Ref |
| Partially vaccinated | 136,570 | 45 | 129 (102–137) | 47,652,852 | 9.4 | 0.74 | 0.55, 1.00 | 0.73 | 0.53, 1.01 | 0.06 |
| Completed primary series with BNT162b2 mRNA (Cominarty-Pfizer/BioNTech) | 1,099,554 | 229 | 127 (78.2–235) | 383,697,568 | 6 | 0.66 | 0.54, 0.76 | 0.62 | 0.52, 0.73 | < 0.01 |
| Recent infection*a | ||||||||||
| None | 2,372,722 | 668 | 242 (131–242) | 827,935,555 | 8.1 | Ref | Ref | Ref | Ref | Ref |
| Recent infection within 6 months | 101,442 | 20 | 132 (76.2–272) | 35,399,227 | 5.6 | 0.69 | 0.44, 1.07 | 0.88 | 0.51, 1.23 | 0.61 |
HR hazard ratio, CI confidence interval, Ref reference category, IQR interquartile range.
aRecent infectionis defined as any infection within 6 months prior to the study period. A reinfection is defined as an infection after a period of 90 or more days since the previous infection.
*Models were adjusted for age, sex, recent infection within 6 months and stratified by region.